Discovery of phenyl acetic acid substituted quinolines as novel liver X receptor agonists for the treatment of atherosclerosis

Journal of Medicinal Chemistry

Volumn 49, Issue 21, 2006, Pages 6151-6154

  Hu, Baihua ^a   Collini, Michael ^a   Unwalla, Rayomand ^a   Miller, Christopher ^a   Singhaus, Robert ^a   Quinet, Elaine ^a   Savio, Dawn ^a   Halpern, Anita ^a   Basso, Michael ^a   Keith, James ^a   Clerin, Valerie ^a   Chen, Liang ^a   Resmini, Christine ^a   Liu, Qiang Yuan ^a   Feingold, Irene ^a   Huselton, Christine ^a   Azam, Farooq ^a   Farnegardh, Mathias ^b   Enroth, Cristofer ^b,c   Bonn, Tomas ^b   Goos Nilsson, Annika ^b   Wilhelmsson, Anna ^b   Nambi, Ponnal ^a   Wrobel, Jay ^a   more..

^a PFIZER INC   (United States)

^b Karo Bio   (Sweden)

^c ÖREBRO UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; GW 3965; LIVER X RECEPTOR; LIVER X RECEPTOR ALPHA; LIVER X RECEPTOR BETA; LOW DENSITY LIPOPROTEIN RECEPTOR; PHENYLACETIC ACID DERIVATIVE; QUINOLINE DERIVATIVE; RECEPTOR BLOCKING AGENT; TO 901317;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CHEMICAL REACTION; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DRUG ACTIVITY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RECEPTOR AFFINITY; TRANSACTIVATION;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; ATP-BINDING CASSETTE TRANSPORTERS; BINDING SITES; BIOLOGICAL AVAILABILITY; CELL LINE; CHOLESTEROL; DNA-BINDING PROTEINS; DRUG STABILITY; FEMALE; HUMANS; LIGANDS; MALE; MICE; MICE, INBRED C57BL; MICROSOMES, LIVER; MODELS, MOLECULAR; MOLECULAR STRUCTURE; ORPHAN NUCLEAR RECEPTORS; PHENYLACETATES; PROTEIN STRUCTURE, TERTIARY; QUINOLINES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; STRUCTURE-ACTIVITY RELATIONSHIP; TRANS-ACTIVATION (GENETICS); TRANSCRIPTIONAL ACTIVATION;

EID: 33750119423     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0609566     Document Type: Article

References (28)

1. For recent reviews, see: (a) Bradley, M. N.; Tontonoz, P. LXR: A nuclear receptor target for cardiovascular disease? Drug Discovery Today 2005, 97-103.
2. (b) Collins, J. L. Therapeutic opportunities for liver X receptor modulators. Curr. Opin. Drug Discovery Dev. 2004, 7, 692-702.
3. (b) Jaye, M. LXR agonists for the treatment of atherosclerosis. Curr. Opin. Invest. Drugs 2003, 4, 1053-1058.
4. (c) Lund, E. G.; Menke, J. G.; Sparrow, C. P. Liver X receptor agonists as potential therapeutic agents for dyslipidemia and atherosclerosis. Arterioscler., Thromb., Vasc. Biol. 2003, 237, 1169-1177.
5. (a) Lehmann, J. M.; Kliewer, S. A.; Moore, L. B.; Smith-Oliver, T. A.; Blanchard, D. E.; Spencer, T. A.; Willson, T. M. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J. Biol. Chem. 1997, 272, 3137-3140.
6. (b) Spencer, T. A.; Gayen, A. K.; Phirwa, S.; Nelson, J. A.; Taylor, F. R.; Kandutsch, A. A.; Erickson, S. K. 24(S), 25-Epoxycholesterol. Evidence consistent with a role in the regulation of hepatic cholesterogenesis. J. Biol. Chem. 1985, 260, 13391-13394.
7. Collins, J. L.; Fivush, A. M.; Watson, M. A.; Galardi, C. M.; Lewis, M. C.; Moore, L. B.; Parks, D. J.; Wilson, J. G.; Tippin, T. K.; Binz, J. G.; Plunket, K. D.; Morgan, D. G.; Beaudet, E. J.; Whitney, K. D.; Kliewer, S. A.; Willson, T. M. Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines. J. Med. Chem. 2002, 45, 1963-1966.
8. Schultz, J. R.; Tu, H.; Luk, A.; Repa, J. J.; Medina, J. C.; Li, L.; Schwendner, S.; Wang, S.; Thoolen, M.; Mangelsdorf, D. J.; Lustig, K. D.; Shan, B. Role of LXRs in control of lipogenesis. Gene Dev. 2000, 14, 2831-2838.
9. Repa, J. J.; Turley, S. D.; Lobaccaro, J.-M. A.; Medina, J.; Li, L.; Lustig, K.; Shan, B.; Heyman, R. A.; Dietschy, J. M.; Mangelsdorf, D. J. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 2000, 289, 1524-1529.
10. (a) Joseph, S. B.; Castrillo, A.; Laffitte, B. A.; Mangelsdorf, D. J.; Tontonoz, P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat. Med. 2003, 9, 213-219.
11. (b) Fowler, A. J.; Sheu, M. Y.; Schmuth, M.; Kao, J.; Fluhr, J. W.; Rhein, L.; Collins, J. L.; Willson, T. M.; Mangelsdorf, D. J.; Elias, P. M.; Feingold, K. R. Liver X receptor activators display anti-inflammatory activity in irritant and allergic contact dermatitis models: Liver-X-receptor-specific inhibition of inflammation and primary cytokine production. J. Invest. Dermatol. 2003, 120, 246-255.
12. LAFβ activity (agonist potency, % agonist activity relative to 3) using CHO cells transfected with hLXRβ and a reporter gene (secreted alkaline phosphatase) driven by multiple response elements for LXR.
13. LXR (β and α) binding using recombinant human LXR binding domains (LBDs) with [3H]T0901317 as a tracer.
14. (a) Faernegardh, M.; Bonn, T.; Sun, S.; Ljunggren, J.; Ahola, H.; Wilhelmsson, A.; Gustafsson, J.-A.; Carlquist, M. The Three-dimensional Structure of the Liver X Receptor β Reveals a Flexible Ligand-binding Pocket That Can Accommodate Fundamentally Different Ligands. J. Biol. Chem. 2003, 278, 38821-38828.
15. (b) Williams, S.; Bledsoe, R. K.; Collins, J. L.; Boggs, S.; Lambert, M. H.; Miller, A. B.; Moore, J.; McKee, D. D.; Moore, L.; Nichols, J.; Parks, D.; Watson, M.; Wisely, B.; Willson, T. M. X-ray Crystal Structure of the Liver X Receptor β Ligand Binding Domain: Regulation by a Histidine-Tryptophan Switch. J. Biol. Chem. 2003, 278, 27138-27143.
16. (a) Svensson, S.; Oestberg, T.; Jacobsson, M.; Norstroem, C.; Stefansson, K.; Hallen, D.; Johansson, I. C.; Zachrisson, K.; Ogg, D.; Jendeberg, L. Crystal structure of the heterodimeric complex of LXRα and RXR ligand-binding domains in a fully agonistic conformation. EMBO J. 2003, 22, 4625-4633.
17. (b) Hoerer, S.; Schmid, A.; Heckel, A.; Budzinski, R.-M.; Nar, H. Crystal structure of the human liver X receptor β ligand-binding domain in complex with a synthetic agonist. J. Mol. Biol. 2003, 334, 853-861.
18. (a) McMartin, C.; Bohacek, R. S. QXP: Powerful, rapid computer algorithms for structure-based drug design. J. Comput.-Aided Mol. Des. 1997, 11, 333-344.
19. (b) InsightII, software package; Accelrys, Inc.: San Diego, CA.
20. (c) Delano, W. L. The PyMOL molecular graphics system 2002 on the World Wide Web; http://www.pymol.org.
21. (a) LXR transactivation assay (% efficacy relative to 3) using Huh7 cells transfected with human LXR LBD fused to Gal4 DBD.
22. (b) For the details of ABCA1, SREBP-1c, and cholesterol efflux assays, see: Quinet, E. M.; Savio, D. A.; Halpern, A. R.; Chen, L.; Miller, C. P.; Nambi, P. Gene-selective modulation by a synthetic oxysterol ligand of the liver X receptor. J. Lipid Res. 2004, 45, 1929-1942.
23. For WY-14643, see: Santilli, A. A.; Scotese, A. C.; Tomarelli, R. M. Potent antihypercholesterolemic agent, [4-chloro-6-(2,3-xylidino)-2- pyrimidinylthio]acetic acid (Wy-14643). Experientia 1974, 30, 1110-1111.
24. For Rosiglitazone, see: Oakes, N. D.; Kennedy, C. J.; Jenkins, A. B.; Laybutt, D. R.; Chisholm, D. J.; Kraegen, E. W. A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes 1994, 43, 1203-1210.
25. For L-796449, see: Lawrence, J. W.; Li, Y.; Chen, S.; DeLuca, J. G.; Berger, J. P.; Umbenhauer, D. R.; Moller, D. E.; Zhou, G. Differential gene regulation in human versus rodent hepatocytes by peroxisome proliferator- activated receptor (PPAR) α: PPARα fails to induce peroxisome proliferation-associated genes in human cells independently of the level of receptor expression. J. Biol. Chem. 2001, 276, 31521-31527.
26. For co-crystalization procedure for 15 with hLXRβ, see ref 9a.
27. The details of the in vivo lesion study for quinoline 15 was presented in the following two posters and will be published elsewhere: (a) Nambi, P.; Basso, M.; Chen, L.; Liu, Q.; Keith, J.; Clerin, V.; Quinet, E.; Savio, D.; Halpern, A.; Wrobel, J. In WAY-254011 inhibits atherosclerotic lesion progression and inflammatory markers in LDL receptor knockout mice. Proceedings of the Keystone Meeting on Nuclear Receptors, Banff, Alberta, Canada, March 18, 2006.
28. (b) Nambi, P.; Basso, M.; Chen, L.; Liu, Q.; Clerin, V.; Feldman, J.; Pittman, D.; Keith, J.; Quinet, E.; Wrobel, J. In WAY-254011, a novel liver X receptor modulator, inhibits atherosclerotic lesion progression in apolipoprotein knockout mice. Proceedings of the XIV International Symposium On Atherosclerosis, Rome, Italy, June 18-22, 2006.